Creative Biostructure provides custom Mempro™ Plant-derived virus-like particels (VLPs) prodution services based on stable transformation system.
VLPs are self-assembled multisubunit protein structures that can mimic native viruses, but are non-infetious owing to the lack of viral genetic materials. Based on this advantage in non-infectiousness, VLPs can be employed for vaccine development. VLPs carrying structurally intact membrane proteins are known as lipoparticles that are widely used for integral membrane protein poduction. Self-assembled VLPs can capture desired membrane proteins and bud off them from the cell membrane without mechanical disruption or detergents, therefore, VLPs become a powerful tool for membrane protein production in a rapid and flexible manner. Most notably, plant-based expression system offers a safe, inexpensive and limitless platform to produce VLPs. Other advantages that plants can offer include: i) the removal of the purification requirement when the plant tissue having the desired recombinant proteins used as the food or feed supplement; ii) the possibility to compartmentalize desired recombinant proteins in different organelles.
Figure 1. Schematic diagram of structural characteristics of virus-like particles (VLPs).
Creative Biostructure can provide plant-derived VLP production using stable transformation system. The significant feature of stable transformation is that the foreign gene is capable of becoming part of the host genome and making the transgene heritable through succeeding generations. Transgenic platns based on stable transformation methodology are economical system for large-scale production of VLPs for vaccine development. The production of VLP in plants can be divided into four process, including:
Cloning and expression of the viral gene of interest in plant cells;
Regeneration and selection of the plants;
Recovery and purification of the protein;
Characterization of the final products.
With plant-based stable transformation platform, the level of VLP accumulation is critical, however, other factors such as plant selection, processing of transgenic plant material, and downstream processing are equally important during VLP production. Creative Biostructure can offer large-scale VLP production using transgenic alfalfa.
We can also provide other various Mempro™ membrane protein production services. Please feel free to contact us for a detailed quote.
A. R. Kusnadi, et al. (1997). Production of recombinant proteins in transgenic plants: practical considerations. Biotechnol. Bioeng., 56: 473-484.
H. S. Mason and M. M. Herbst-Kralovetz (2012). Plant-derived antigens as mucosal vaccines. Curr. Top Microbiol. Immunol., 354: 101-120.
J. Marsian and G. P. Lomonossoff (2016). Molecular pharming - VLPs made in plants. Curr. Opion Biotech., 37: 201-206.
Q. Chen and H. Lai (2013). Plant-derived virus-like particles as vaccines. Hum. Vaccin. Immunother., 9(1): 26-49.
R. Huang, et al. (2016). Generating recombinant antibodies to membrane proteins through phage display. Antibodies, 5(2): 11.